Population: Immunocompromised patients

Pfizer C5091018

Argentina Belgium Brazil Denmark France Germany Greece Japan Mexico Netherlands Puerto Rico Slovakia South Korea Spain Sweden Taiwan Türkiye United States of America
|
2025-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Ibuzatrelvir

INVENT

United Kingdom United States
|
2025-2026
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Human metapneumovirus
  • Parainfluenza Virus
  • Pharmacological intervention
  • Antivirals
  • SNG001